Wegovy vs Ozempic: Cost and Access Head-to-Head

Same Molecule, Different Approvals

Wegovy and Ozempic are both semaglutide. The active peptide is chemically identical. What differs is the maximum approved dose, the pen device, the titration schedule, and, most consequentially for patients, the FDA-approved indication that determines insurance access.

FDA Labeling Drives Everything Downstream

Wegovy received FDA approval on June 4, 2021, specifically for chronic weight management in adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes [1]. Ozempic's label, by contrast, covers glycemic control in adults with type 2 diabetes and, since 2020, cardiovascular risk reduction in T2D patients with established cardiovascular disease [2].

That labeling difference is not a technicality. Insurers and pharmacy benefit managers use the FDA indication to classify a drug as either a diabetes agent (often covered) or an anti-obesity medication (often excluded). The American Diabetes Association 2024 Standards of Care recommend semaglutide by name for T2D patients who need weight loss or CV risk reduction, which reinforces Ozempic's formulary position in diabetes benefits [3].

Dose Ceiling Matters for Weight Loss

The 2.4 mg weekly dose in Wegovy is meaningfully higher than the 1 mg or 2 mg ceiling in Ozempic. Higher receptor occupancy at the GLP-1 receptor translates directly into greater appetite suppression and greater weight loss. That dose-response relationship is why the FDA required a dedicated obesity-indication trial program (STEP) rather than simply relabeling Ozempic.

Efficacy: What the Trial Data Actually Show

Weight-loss outcomes depend on the dose used and the population studied. Comparing STEP-1 with SUSTAIN-7 is not a true head-to-head, but the numbers illustrate what the dose difference produces in practice.

STEP-1: Wegovy 2.4 mg in Adults With Obesity

STEP-1 enrolled 1,961 adults without type 2 diabetes. Participants had a mean BMI of 37.9 kg/m² and received either semaglutide 2.4 mg or placebo once weekly for 68 weeks, alongside a reduced-calorie diet and physical activity counseling.

Semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight compared with 2.4% in the placebo group (P<0.001) [4]. That translates to approximately 15.3 kg lost on the active drug. More than 86% of semaglutide participants lost at least 5% of body weight, and 69.1% lost at least 10%.

SUSTAIN-7: Ozempic 1 mg in Type 2 Diabetes

SUSTAIN-7 was a randomized, open-label trial comparing semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks in 1,201 adults with type 2 diabetes inadequately controlled on metformin [5].

Semaglutide 1.0 mg produced a mean weight reduction of 6.5 kg versus 3.0 kg for dulaglutide 1.5 mg (P<0.001) [5]. HbA1c dropped 1.8 percentage points with semaglutide 1.0 mg. The trial was not designed to measure weight loss as the primary endpoint; glycemic control was the focus. Weight loss was a secondary finding in a T2D population that differs substantially from the STEP-1 cohort.

Why You Cannot Directly Compare These Numbers

Patients in STEP-1 had obesity without diabetes. Patients in SUSTAIN-7 had T2D, which blunts GLP-1 receptor sensitivity and is associated with medications (sulfonylureas, insulin) that cause weight gain. The dose in SUSTAIN-7 was 1 mg, not 2.4 mg. The trial lengths differed by 28 weeks. Direct number-to-number comparison overstates or understates the drug effect depending on which direction you read it.

What the data do support: higher semaglutide doses produce greater weight loss, and patients without T2D who receive 2.4 mg achieve roughly double the percentage weight loss seen in T2D patients on 1 mg [4][5].

Cost Comparison: List Price vs What You Pay

Wholesale Acquisition Cost in 2025

Novo Nordisk's published wholesale acquisition cost (WAC) for Wegovy in 2025 is approximately $1,349 per 28-day supply of the 2.4 mg maintenance dose. Ozempic's WAC runs approximately $935 for the 0.5 mg/1 mg pen and $1,029 for the 2 mg pen per 28-day supply. These are pre-negotiation prices and do not reflect what most commercially insured patients pay at the pharmacy counter.

The FDA's drug pricing transparency resources confirm that WAC is the manufacturer's list price before any rebates negotiated by pharmacy benefit managers, which can reduce the net price by 40 to 60% in commercial plans [6].

Insurance Coverage: The Biggest Variable

Commercial insurance coverage for Wegovy remains inconsistent. A 2023 analysis published in JAMA Health Forum found that only about 39% of large employer health plans covered anti-obesity medications at all [7]. When coverage exists, prior-authorization requirements typically demand a BMI of 30 or greater (or 27 with comorbidity), documentation of a prior structured weight-loss attempt, and often a prescriber attestation that the patient is enrolled in a behavioral program.

Ozempic coverage is substantially broader. Because it is a diabetes drug, most commercial formularies include it, often in Tier 2 or Tier 3. Medicare Part D covers Ozempic for T2D but, under the current statutory exclusion for weight-loss drugs, does not cover Wegovy, though the Treat and Reduce Obesity Act, if passed, would change this [8].

Manufacturer Savings Programs

Novo Nordisk operates savings card programs for both drugs. Commercially insured patients who qualify can pay as little as $25 per month for Wegovy through the WeGoTogether savings card, with a monthly cap of $200 for those who do not qualify for the lowest tier. The Ozempic savings offer caps eligible patients at $99 per month. Neither program applies to Medicare, Medicaid, or other government-funded coverage [9].

Compounded Semaglutide: A Cost Option With Caveats

During the 2022 to 2024 shortage period, the FDA placed semaglutide on its drug shortage list, which allowed 503A and 503B compounding pharmacies to produce semaglutide injections legally. Compounded versions were often priced at $200, $400/month, significantly below branded list prices.

As of early 2025, the FDA removed injectable semaglutide from the shortage list and has been taking enforcement action against compounders continuing to produce it [10]. Patients currently on compounded semaglutide should discuss a transition plan with their prescriber, since the legal and safety status of compounded products has changed materially.

Access Pathways: How Patients Get Each Drug

Wegovy Access

A prescriber must document an obesity diagnosis (ICD-10 E66.x) and confirm BMI meets threshold. For commercial insurance, a prior-authorization form typically requires [2][9]:

• BMI documentation from a clinical visit within the prior 12 months
• Evidence of at least one weight-related comorbidity if BMI is 27 to 29.9 kg/m²
• Documentation that the patient has attempted lifestyle modification
• Prescriber attestation that adjunctive behavioral counseling is planned

Telehealth prescribers, including HealthRX clinicians, can initiate Wegovy if the patient meets criteria. Most telehealth platforms require a synchronous video visit or a comprehensive asynchronous intake that meets state prescribing standards before sending the prescription to a preferred specialty pharmacy.

Ozempic Access for Off-Label Weight Loss

Ozempic is frequently prescribed off-label for weight loss in patients who do not have type 2 diabetes. Prescribing it off-label is legal, but it creates two practical problems. First, insurance will not cover it for a non-diabetes diagnosis, meaning the patient pays cash or uses a savings card. Second, the maximum approved dose is 2.0 mg, not 2.4 mg, so the patient never reaches the dose proven in STEP-1.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Clinicians should prescribe anti-obesity medications that are FDA-approved for chronic weight management rather than medications approved for other indications, unless a specific clinical reason exists for an alternative approach" [11]. That guidance favors Wegovy for weight-loss goals in patients who can access it.

Step Therapy and Formulary Restrictions

Some payers require step therapy, meaning they mandate a trial of a lower-cost drug before approving Wegovy. Common step requirements include a 3-month trial of orlistat, phentermine-topiramate, or naltrexone-bupropion. Appeals are possible and succeed more often when the prescriber submits peer-reviewed evidence, including STEP-1 outcomes, and documents contraindications to the required step agent.

Titration Schedules and Pen Devices

Wegovy Titration

Wegovy uses a five-step titration over 16 weeks to reach the 2.4 mg maintenance dose:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly

Each dose strength comes in a separate single-dose pen. The prescriber writes five separate prescriptions (or one prescription with step instructions) to cover the titration period [1].

Ozempic Titration

Ozempic uses a simpler schedule. Patients start at 0.25 mg for 4 weeks, then advance to 0.5 mg. The 0.5 mg dose may be maintained or increased to 1 mg after at least 4 weeks. The 2 mg dose requires at least 4 weeks at 1 mg before advancing. A single multi-dose pen delivers multiple injections before it is discarded, which differs from Wegovy's single-use pens [2].

The device difference affects supply chain logistics. Wegovy shortages during 2022 to 2024 were partly attributable to the higher number of pen units required per patient per year.

Side Effect Profile: Effectively the Same Drug

Because the active molecule is identical, the adverse-event profiles of Wegovy and Ozempic overlap almost completely. Nausea, vomiting, diarrhea, and constipation are the most common, affecting 40 to 50% of patients in the first 8 to 12 weeks of titration in STEP-1 and SUSTAIN trials [4][5].

Rare but serious risks include:

• Acute pancreatitis (incidence approximately 0.2% in STEP-1) [4]
• Gallbladder disease, including cholelithiasis (1.6% in STEP-1 vs 0.7% placebo) [4]
• Thyroid C-cell tumors (black-box warning; based on rodent data, human relevance unknown) [1][2]
• Heart rate increase of approximately 2 to 3 beats per minute at steady state [12]

Both drugs carry an identical contraindication list: personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes [13]. This finding supports the use of Wegovy specifically in patients with CVD who do not have T2D, a population that would not qualify for Ozempic on-label.

Which Drug Is Right for Which Patient?

The decision typically follows a straightforward clinical pathway based on diagnosis and payer:

Patient has type 2 diabetes, needs glycemic control and some weight loss. Ozempic is on-label, likely covered, and appropriate. The 2.0 mg dose achieves meaningful HbA1c reduction and moderate weight loss [5][2].

Patient has obesity (BMI ≥30 or ≥27 with comorbidity) without T2D, needs maximum weight loss. Wegovy is on-label. If commercial insurance covers anti-obesity medications, prior-authorize Wegovy. If coverage is denied, evaluate savings-card pricing or appeal with STEP-1 data.

Patient has both T2D and obesity. Either drug could be justified. The Endocrine Society guideline leans toward the obesity-approved agent when weight loss is the primary goal, given the higher dose ceiling [11]. Some clinicians start with Ozempic (covered under diabetes benefit), then transition to Wegovy once the patient has demonstrated response and the prescriber can document the need for the higher dose.

Patient cannot afford either branded drug. Compounded semaglutide is no longer legally available from most compounders following FDA enforcement actions in early 2025 [10]. Alternatives include tirzepatide (Zepbound for obesity, Mounjaro for T2D), liraglutide (Victoza/Saxenda), or a savings-card-assisted pathway for branded semaglutide.

Switching Between Wegovy and Ozempic

Switching is pharmacologically straightforward because the molecule is the same. A patient transitioning from Ozempic 1 mg to Wegovy 1.7 mg or 2.4 mg does not need to re-titrate from 0.25 mg; the prescriber can typically continue at the equivalent or next dose tier, depending on tolerability at the current dose [1][2].

Switching from Wegovy 2.4 mg back to Ozempic reduces the dose by 0.4 mg (since the highest Ozempic dose is 2.0 mg). Patients may notice slightly reduced appetite suppression after this step-down, but no safety washout period is required. The prescriber should document the clinical reason for the switch, particularly if insurance is involved, since a switch from a covered diabetes drug to an uncovered obesity drug (or vice versa) can trigger a new prior-authorization requirement.

A transition note should include current dose, date of last injection, reason for switch, and updated weight and BMI to support any coverage documentation [11].